Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

6262 ARTÍCULOS , VIENDO DEL 2401 AL 2415

Small molecule modulators of alpha-synuclein aggregation and toxicity: Pioneering an emerging arsenal against Parkinson's disease

Ahanger IA, Dar TA.

Ageing Res Rev. 2024 Nov;101:102538. doi: 10.1016/j.arr.2024.102538. Epub 2024 Oct 9.

Role and Diagnostic Significance of Apolipoprotein D in Selected Neurodegenerative Disorders

Kolanek A, Cemaga R, Maciejczyk M.

Diagnostics (Basel). 2024 Dec 14;14(24):2814. doi: 10.3390/diagnostics14242814.

Polyphenols Targeting NF-κB Pathway in Neurological Disorders: What We Know So Far?

Mamun AA, Shao C, Geng P, Wang S, Xiao J.

Int J Biol Sci. 2024 Jan 27;20(4):1332-1355. doi: 10.7150/ijbs.90982. eCollection 2024.

Subcutaneous Levodopa: A New Engine for the Vintage Molecule

Poplawska-Domaszewicz K, Batzu L, Falup-Pecurariu C, Chaudhuri KR.

Neurol Ther. 2024 Aug;13(4):1055-1068. doi: 10.1007/s40120-024-00635-4. Epub 2024 Jun 14.

The Neurological Implications of COVID-19: A Comprehensive Narrative Review

Cheyne I, Gopinath VS, Muppa N, Armas AE, Gil Agurto MS, Akula SA, Nagpal S, Yousaf MS, Haider A.

Cureus. 2024 May 15;16(5):e60376. doi: 10.7759/cureus.60376. eCollection 2024 May.

A critical appraisal of ferroptosis in Alzheimer's and Parkinson's disease: new insights into emerging mechanisms and therapeutic targets

Soni P, Ammal Kaidery N, Sharma SM, Gazaryan I, Nikulin SV, Hushpulian DM, Thomas B.

Front Pharmacol. 2024 Jul 8;15:1390798. doi: 10.3389/fphar.2024.1390798. eCollection 2024.

Postbiotics as Molecules Targeting Cellular Events of Aging Brain-The Role in Pathogenesis, Prophylaxis and Treatment of Neurodegenerative Diseases

Głowacka P, Oszajca K, Pudlarz A, Szemraj J, Witusik-Perkowska M.

Nutrients. 2024 Jul 12;16(14):2244. doi: 10.3390/nu16142244.

Blood-brain barrier alterations and their impact on Parkinson's disease pathogenesis and therapy

Lau K, Kotzur R, Richter F.

Transl Neurodegener. 2024 Jul 29;13(1):37. doi: 10.1186/s40035-024-00430-z.

Neurodegenerative diseases and catechins: (-)-epigallocatechin-3-gallate is a modulator of chronic neuroinflammation and oxidative stress

Li S, Wang Z, Liu G, Chen M.

Front Nutr. 2024 Aug 1;11:1425839. doi: 10.3389/fnut.2024.1425839. eCollection 2024.

The crucial role of VPS35 and SHH in Parkinson's disease: Understanding the mechanisms behind the neurodegenerative disorder

Bhardwaj K, Jha A, Roy A, Kumar H.

Brain Res. 2024 Dec 15;1845:149204. doi: 10.1016/j.brainres.2024.149204. Epub 2024 Aug 27.

Clinical pharmacokinetics of levodopa and relevant add-on therapies for Parkinson's disease

Müller T.

Expert Opin Drug Metab Toxicol. 2024 Nov 11. doi: 10.1080/17425255.2024.2428831. Online ahead of print.

PrP meets alpha-synuclein: Molecular mechanisms and implications for disease

Vieira TCRG, Barros CA, Domingues R, Outeiro TF.

J Neurochem. 2024 Aug;168(8):1625-1639. doi: 10.1111/jnc.15992. Epub 2023 Oct 19.

The Influence of Myeloid-Derived Suppressor Cell Expansion in Neuroinflammation and Neurodegenerative Diseases

Tamberi L, Belloni A, Pugnaloni A, Rippo MR, Olivieri F, Procopio AD, Bronte G.

Cells. 2024 Apr 6;13(7):643. doi: 10.3390/cells13070643.

Role of the Insulin-like Growth Factor System in Neurodegenerative Disease

Lewitt MS, Boyd GW.

Int J Mol Sci. 2024 Apr 20;25(8):4512. doi: 10.3390/ijms25084512.

The misfolding mystery: α-synuclein and the pathogenesis of Parkinson's disease

Negi S, Khurana N, Duggal N.

Neurochem Int. 2024 Jul;177:105760. doi: 10.1016/j.neuint.2024.105760. Epub 2024 May 7.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias